drugset
Drugs / pp65/tumor mRNA RNA-LP (DP2)
last change Mar 2025 re-read 3 minutes ago

pp65/tumor mRNA RNA-LP (DP2)

Messenger RNA (mRNA)

Developed for
malignant glioma · osteosarcoma
Investigated by
Alex's Lemonade Stand Foundation · National Cancer Institute (NCI) · National Pediatric Cancer Foundation · The Osteosarcoma Institute · The V Foundation for Cancer Research · University of Florida

Trials 1

today NCT05660408 · Ph 1/2
2025202620272028202920302031203220332034
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05660408 Mar 2025 → Oct 2033 expected malignant glioma, osteosarcoma University of Florida Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as pp65/tumor mRNA RNA-LP (DP2) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05660408 ↗
Modality Messenger RNA (mRNA) “pp65/tumor mRNA RNA-LP (DP2) vaccinations” NCT05660408 ↗